Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gedeon Richter plc
Industry Sector: HealthTechnology
CEO: Gábor Orbán
Number Of Employees: N/A
Enterprise Value: $4,551,331,456
PE Ratio: 7.9
Exchange/Ticker 1: Budapest:RICHTER
Exchange/Ticker 2: N/A
Latest Market Cap: $5,195,497,693
BioCentury | Dec 20, 2022
Deals
Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal
Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more
BioCentury | Mar 15, 2022
Finance
March 14 Quick Takes: Arch refills Nutcracker with $167M series C
Plus Ascendis meets in hypoparathyroidism and updates from BridgeBio, AZ, Sanofi, Pfizer and more
BioCentury | Oct 30, 2021
Product Development
Oct. 29 Quick Takes: The Rise and Fall of Sputnik V
Plus FDA approves Novartis’ first-in-class STAMP inhibitor for CML and IPOs from Entrada, Aura and more
BioCentury | Apr 2, 2020
Product Development
April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more
BioCentury | Nov 11, 2019
Emerging Company Profile
Mycovia tackling chronic infections with antifungal pipeline
Mycovia aims to treat chronic fungal infections with safer CYP51 inhibitors
BioCentury | May 28, 2019
Company News
May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more
BioCentury | Apr 6, 2018
Clinical News
Allergan's cariprazine meets again in Phase III for bipolar I depression
BioCentury | Apr 3, 2018
Clinical News
Allergan's cariprazine meets again in Phase III for bipolar I depression
Items per page:
1 - 10 of 25